WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted
anticancer therapies using its industry leading antibody-drug conjugate
(ADC) technology, today announced the appointment of David Johnston as
Executive Vice President and Chief Financial Officer, effective today.
Mr. Johnston brings to ImmunoGen more than 30 years of experience in
corporate finance, including 15 years in senior financial functions at
biotechnology companies, as well as extensive experience in corporate
planning. He reports to Daniel Junius, President and Chief Executive
Officer of ImmunoGen.
"I am delighted to have Dave join ImmunoGen," commented Mr. Junius. "His
depth of experience in both senior financial positions and in corporate
planning makes Dave well-suited to help successfully advance the Company
to our next stages."
Mr. Johnston joins ImmunoGen from AVEO Pharmaceuticals Inc., where he
was the CFO. Prior to joining AVEO in 2007, Mr. Johnston was Senior Vice
President of Finance, Corporate Planning and Analysis at Genzyme
Corporation and, before that, the VP Finance and CFO of Genzyme
Biosurgery. Prior to joining Genzyme in 1998, Mr. Johnston held
financial, planning and analysis positions of increasing responsibility
at several major corporations. He holds a BS degree from Washington and
Lee University and an MBA from the University of Michigan.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses a tumor-targeting engineered antibody to deliver one
of ImmunoGen's highly potent cancer-cell killing agents specifically to
tumor cells; the Company has also developed antibodies with anticancer
activity of their own. The most advanced compound with ImmunoGen's ADC
technology is Roche's Kadcyla®, which is marketed in the US
by Genentech and is also gaining approvals internationally. Additional
compounds are in clinical testing by ImmunoGen and through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademarks of Genentech, Inc., a
member of the Roche Group.
Carol Hausner, 781-895-0600
Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media